Matt DeNardo
speaker
183 appearances
1 recordings
1 series
first heard Jul 2026
last heard 11 Jul
Matt DeNardo’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.
Appearances
But I can imagine that folks that are doing larger studies would also benefit from that.
that type of situation.
And obviously that one is unique to Boston, whereas folks at other places in the U.S.
may have direct flights and connections elsewhere.
But it does seem that Panama City is kind of an airline hub for much of Latin America.
So if you can go anywhere else in Latin America, you can mostly also go to Panama City.
So that was very convenient for us.
I think what helped us a lot in working with BioAccess was building the relationship with them as a CRO first, before we really started exploring the clinical sites and the clinical folks that we would meet at those sites.
And I think that worked out really well because
It helped us work with BioAccess less as a consulting CRO and more as an extension of our clinical team.
And I think that was a really important distinction because
After a series of introductory meetings, the BioAccess team understood what we were trying to achieve.
They understood more about our device and that helped them translate both literally and figuratively to the clinical teams that they were meeting at our potential study sites and speak in our voice almost to those teams.
And I think it was really important for us to do that work upfront with Bioaccess to have that level of alignment going forward.
It also meant that communication later on could be more streamlined because they already had in their heads from working with us, like what answers to typical questions would be.
And because they knew what we were getting at,
They didn't have to turn into every conversation being a back and forth translation where they could speak on our behalf for certain things.
And that would help manage the relationship with the clinical site.
And I think also show the clinical sites that we're working with, that they were a CRO that knew what they were talking about.
So it wasn't just serving as a conduit for ACSOF to work with the clinical site.
Showing 81–100 of 183 · page 5 of 10
← Previous
Next →